专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2004039385A2 PHARMACEUTICAL COMPOSITIONS AND USES COMPRISING MUCUNA PRURIENS SEED POWDER AND EXTRACTS THEREOF IN THE TREATMENT OF NEUROLOGICAL DISEASES 审中-公开
标题翻译：药物组合物及其使用包括MUCUNA PRURIENS种子粉末及其在治疗神经病中的提取物
公开(公告)号：WO2004039385A2
公开(公告)日：2004-05-13
申请号：PCT/EP2003/010975
申请日：2003-10-02
申请人： PHYTRIX AG , VAN DER GIESSEN, Rob , OLANOW, Waren, C. , LEES, Andrew , WAGNER, Hildebert
发明人： VAN DER GIESSEN, Rob , OLANOW, Waren, C. , LEES, Andrew , WAGNER, Hildebert
IPC分类号： A61K35/78
CPC分类号： A61K36/48
摘要： The present invention provides pharmaceutical compositions comprising Mucuna pruriens seeds or one or more Mucuna pruriens seed components, substances, fractions or mixtures or substances obtained therefrom. Furthermore, the invention relates to the use of Mucuna pruriens seed powder or one or more Mucuna pruriens components, substances, fractions or mixtures or substances obtained therefrom for the preparation of a pharmaceutical composition for preventing, alleviating or treating neurological diseases. Additionally, the invention relates to the use of Mucuna pruriens seeds for the preparation of a pharmaceutical composition for neuroprotection or neurostimulation and to methods of preparing extracts of Mucuna pruriens which can be used for the preparation of a pharmaceutical composition for treating neurological diseases. Finally, the invention relates to the use of Mucuna pruriens seeds for the preparation of a pharmaceutical composition for the treatment of Parkinson's Disease to obtain a broader therapeutic window in L-Dopa therapy, to delay a need for combination therapy, to obtain an earlier onset and longer duration of L-Dopa efficacy, and to prevent or alleviate acute and chronic L-Dopa toxicity.
摘要翻译：本发明提供了包含Mucuna pruriens种子或一种或多种Mucuna pruriens种子组分，从其获得的物质，级分或混合物或物质的药物组合物。此外，本发明涉及用于制备用于预防，减轻或治疗神经疾病的药物组合物的Mucuna pruriens种子粉末或一种或多种Mucuna pruriens组分，物质，级分或由其获得的混合物或物质的用途。此外，本发明涉及Mucuna pruriens种子用于制备神经保护或神经刺激的药物组合物的用途，以及可用于制备用于治疗神经疾病的药物组合物的Mucuna pruriens提取物的方法。最后，本发明涉及Mucuna pruriens种子用于制备用于治疗帕金森病的药物组合物以在L-多巴治疗中获得更广泛的治疗窗口，延迟联合治疗的需要以获得较早发病的用途延长持续时间的L-多巴功效，并预防或缓解急性和慢性左旋多巴的毒性。

2. 发明申请

WO02087600A8 USE OF PHYLLANTHUS CONSTITUENTS FOR TREATING OR PREVENTING INFECTIONS CAUSED BY HEPATIT 审中-公开
标题翻译：叶下珠由病毒治疗或预防乙肝感染中的用途
公开(公告)号：WO02087600A8
公开(公告)日：2002-12-12
申请号：PCT/EP0204641
申请日：2002-04-26
申请人： PHYTRIX AG , OTT MICHAEL , MANNS MICHAEL P
发明人： OTT MICHAEL , MANNS MICHAEL P
IPC分类号： A61K9/06 , A61K9/08 , A61K9/16 , A61K9/20 , A61K31/513 , A61K31/52 , A61K36/00 , A61K36/47 , A61K38/21 , A61P1/16 , A61P31/12 , A61P31/20 , A61P35/00 , A61P43/00 , A61K35/78
CPC分类号： A61K36/47 , Y10S514/894 , A61K2300/00
摘要： The invention relates to the use of one or more Phyllanthus constituent(s) or substances or substance mixtures obtained therefrom for preventing or treating infectious diseases caused by a hepatitis B virus that is resistant to nucleoside analogues or in the event that a hepatitis B virus, which is resistant to nucleoside analogues, is involved in the development or progression of infectious diseases. The invention also relates to the use of one or more Phyllanthus constituent(s) or substances or substance mixtures obtained therefrom for producing a medicament used for preventing or treating infectious diseases caused by a hepatitis B virus that is resistant to nucleoside analogues or in the event that a hepatitis B virus, which is resistant to nucleoside analogues, is involved in the development or progression of infectious diseases. The invention additionally relates to the use of one or more Phyllanthus constituent(s) or substances or substance mixtures obtained therefrom for inhibiting the propagation of a hepatitis B virus that is resistant to nucleoside analogues. The invention also refers to methods for preventing or treating infectious diseases in a mammal caused by a hepatitis B virus that is resistant to nucleoside analogues or in the event that a hepatitis B virus, which is resistant to nucleoside analogues, is involved in the development or progression of infectious diseases, whereby one or more Phyllanthus constituent(s) or substances or substance mixtures obtained therefrom is/are administered to the mammal. The invention further refers to methods for inhibiting the propagation of a hepatitis B virus that is resistant to nucleoside analogues, whereby one or more Phyllanthus constituent(s) or substances or substance mixtures obtained therefrom is/are brought into contact with the viruses. In a preferred embodiment of the invention, the nucleoside analogues are selected from the group comprised of lamivudine and famciclovir.
摘要翻译：本发明涉及使用一个或多个余甘成分（S）的或衍生的用于预防或治疗感染性疾病，这是由乙型肝炎病毒，其是耐核苷类似物，或它们的发展或进展肝炎引起的物质或组合物 B病毒，它对核苷类似物有抗性。此外，本发明涉及使用一个或多个余甘成分（S）或者衍生的物质或物质混合物的用于感染性疾病，其由乙型肝炎病毒具有抗性引起核苷类似物，或预防或治疗的药物中的用途及其发展或进展涉及对核苷类似物具有抗性的乙型肝炎病毒。本发明还涉及使用一种或多种余甘成分（S）或者衍生的物质或组合物用于抑制乙型肝炎病毒这是核苷类似物有抗性的增殖。此外，本发明涉及一种用于预防或治疗感染性疾病中引起的乙型肝炎病毒是耐核苷类似物，或它们的发展或进展的B型肝炎病毒，其是核苷类似物有抗性的哺乳动物，所涉及的方法其中向所述哺乳动物施用一种或多种余下的余下组分或其物质或其混合物。此外，本发明涉及用于抑制乙型肝炎病毒这是核苷类似物，其中一个或多个叶下珠属成分（S）或其衍生物质或物质混合物与病毒的抵接抗性的增殖的方法。在本发明的优选实施方案中，核苷类似物选自拉米夫定和泛昔洛韦。

3. 发明申请

WO02088343A3 RECOMBINANT EXPRESSION OF hHBV REVERSE TRANSCRIPTASE (RT) 审中-公开
标题翻译： hHBV逆转录酶（RT）的重组表达
公开(公告)号：WO02088343A3
公开(公告)日：2003-04-24
申请号：PCT/EP0204642
申请日：2002-04-26
申请人： PHYTRIX AG , BUCHNER JOHANNES , MUSCHLER PAUL , HALSBECK MARTIN
发明人： BUCHNER JOHANNES , MUSCHLER PAUL , HALSBECK MARTIN
IPC分类号： C12N15/09 , A61K36/00 , A61K36/47 , A61K45/00 , A61P1/16 , A61P31/20 , A61P43/00 , C12N9/12 , C12N15/10 , C12N15/62 , C12N15/70 , C12P19/34 , C12Q1/18 , C12Q1/48 , G01N33/68
CPC分类号： C12N9/1276 , C07K2319/00
摘要： The present invention relates to a method of producing a functional cell-free hepatitis B virus (HBV) reverse transcriptase (RT) comprising the steps of expressing HBV-RT in E. coli cells employing a suitable expression plasmid, or in a cell-free transcription-translation system and if expression was carried out in E. coli cells, lysing said E. coli cells and purifying HBV-RT from E. coli lysate or from said transcription-translation system. The invention further relates to a method of screening for an inhibitor of HBV-RT activity comprising the steps of contacting the cell-free HBV-RT produced according to methods of the present invention and with a potential inhibitor and assaying whether said potential inhibitor inhibits HBV-RT activity. Furthermore, the invention provides for a method of producing a pharmaceutical composition comprising the step of formulating the inhibitor identified by the screening method of the invention into a pharmaceutical composition.
摘要翻译：本发明涉及一种生产功能性无细胞乙型肝炎病毒（HBV）逆转录酶（RT）的方法，包括以下步骤：使用合适的表达质粒在大肠杆菌细胞中表达HBV-RT，或以无细胞转录翻译系统，并且如果在大肠杆菌细胞中进行表达，则将大肠杆菌细胞裂解并从大肠杆菌裂解物或所述转录翻译系统中纯化HBV-RT。本发明还涉及一种筛选HBV-RT活性抑制剂的方法，包括以下步骤：将根据本发明方法产生的无细胞HBV-RT与潜在的抑制剂接触，并测定所述潜在抑制剂是否抑制HBV -RT活动。此外，本发明提供了制备药物组合物的方法，其包括将通过本发明的筛选方法鉴定的抑制剂配制成药物组合物的步骤。

4. 发明申请

WO2002088343A2 RECOMBINANT EXPRESSION OF hHBV REVERSE TRANSCRIPTASE (RT) 审中-公开
标题翻译： hHBV逆转录酶（RT）的重组表达
公开(公告)号：WO2002088343A2
公开(公告)日：2002-11-07
申请号：PCT/EP2002/004642
申请日：2002-04-26
申请人： PHYTRIX AG , BUCHNER, Johannes , MUSCHLER, Paul , HALSBECK, Martin
发明人： BUCHNER, Johannes , MUSCHLER, Paul , HALSBECK, Martin
IPC分类号： C12N9/12
CPC分类号： C12N9/1276 , C07K2319/00
摘要： The present invention relates to a method of producing a functional cell-free hepatitis B virus (HBV) reverse transcriptase (RT) comprising the steps of expressing HBV-RT in E. coli cells employing a suitable expression plasmid, or in a cell-free transcription-translation system and if expression was carried out in E. coli cells, lysing said E. coli cells and purifying HBV-RT from E. coli lysate or from said transcription-translation system. The invention further relates to a method of screening for an inhibitor of HBV-RT activity comprising the steps of contacting the cell-free HBV-RT produced according to methods of the present invention and with a potential inhibitor and assaying whether said potential inhibitor inhibits HBV-RT activity. Furthermore, the invention provides for a method of producing a pharmaceutical composition comprising the step of formulating the inhibitor identified by the screening method of the invention into a pharmaceutical composition.
摘要翻译：本发明涉及一种生产功能性无细胞乙型肝炎病毒（HBV）逆转录酶（RT）的方法，包括以下步骤：使用合适的表达质粒在大肠杆菌细胞中表达HBV-RT，或以无细胞转录翻译系统，并且如果在大肠杆菌细胞中进行表达，则将大肠杆菌细胞裂解并从大肠杆菌裂解物或所述转录翻译系统中纯化HBV-RT。本发明还涉及一种筛选HBV-RT活性抑制剂的方法，包括以下步骤：将根据本发明方法产生的无细胞HBV-RT与潜在的抑制剂接触，并测定所述潜在抑制剂是否抑制HBV -RT活动。此外，本发明提供了制备药物组合物的方法，其包括将通过本发明的筛选方法鉴定的抑制剂配制成药物组合物的步骤。

5. 发明申请

US20060165822A1 Pharmaceutical compositions and uses comprising mucuna pruriens seed powder and extracts thereof in the treatment of neurological diseases 有权
标题翻译：药物组合物和用途，其包括粘液普鲁斯种子粉及其提取物在治疗神经疾病中的用途
公开(公告)号：US20060165822A1
公开(公告)日：2006-07-27
申请号：US10533135
申请日：2003-10-02
申请人： Rob Van Der Giessen , C Olanow , Andrew Lees , Hildebert Wagner
发明人： Rob Van Der Giessen , C Olanow , Andrew Lees , Hildebert Wagner
IPC分类号： A61K36/48
CPC分类号： A61K36/48
摘要： The present invention provides pharmaceutical compositions comprising Mucuna pruriens seeds or one or more Mucuna pruriens seed components, substances, fractions or mixtures or substances obtained therefrom. Furthermore, the invention relates to the use of Mucuna pruriens seed powder or one or more Mucuna pruriens components, substances, fractions or mixtures or substances obtained therefrom for the preparation of a pharmaceutical composition for preventing, alleviating or treating neurological diseases. Additionally, the invention relates to the use of Mucuna pruriens seeds for the preparation of a pharmaceutical composition for neuroprotection or neurostimulation and to methods of preparing extracts of Mucuna pruriens which can be used for the preparation of a pharmaceutical composition for treating neurological diseases. Finally, the invention relates to the use of Mucuna pruriens seeds for the preparation of a pharmaceutical composition for the treatment of Parkinson's Disease to obtain a broader therapeutic window in L-Dopa therapy, to delay a need for combination therapy, to obtain an earlier onset and longer duration of L-Dopa efficacy, and to prevent or alleviate acute and chronic L-Dopa toxicity.
摘要翻译：本发明提供了包含Mucuna pruriens种子或一种或多种Mucuna pruriens种子组分，从其获得的物质，级分或混合物或物质的药物组合物。此外，本发明涉及用于制备用于预防，减轻或治疗神经疾病的药物组合物的Mucuna pruriens种子粉或一种或多种Mucuna pruriens组分，物质，级分或由其获得的混合物或物质的用途。此外，本发明涉及Mucuna pruriens种子用于制备神经保护或神经刺激的药物组合物的用途，以及可用于制备用于治疗神经疾病的药物组合物的Mucuna pruriens的提取物的方法。最后，本发明涉及Mucuna pruriens种子用于制备用于治疗帕金森病的药物组合物以在L-多巴治疗中获得更广泛的治疗窗口，延迟联合治疗的需要以获得较早发病的用途延长持续时间的L-多巴功效，并预防或缓解急性和慢性左旋多巴的毒性。

6. 发明申请

WO2004039385A3 MUCUNA PRURIENS AND EXTRACTS THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISEASES 审中-公开
标题翻译： MUCUNA PRURIENS及其提取物治疗神经病
公开(公告)号：WO2004039385A3
公开(公告)日：2004-07-01
申请号：PCT/EP0310975
申请日：2003-10-02
申请人： PHYTRIX AG , VAN DER GIESSEN ROB , OLANOW WAREN C , LEES ANDREW , WAGNER HILDEBERT
发明人： VAN DER GIESSEN ROB , OLANOW WAREN C , LEES ANDREW , WAGNER HILDEBERT
IPC分类号： A61K36/48 , A61P25/16 , A61K35/78
CPC分类号： A61K36/48
摘要： The present invention provides pharmaceutical compositions comprising Mucuna pruriens seeds or one or more Mucuna pruriens seed components, substances, fractions or mixtures or substances obtained therefrom. Furthermore, the invention relates to the use of Mucuna pruriens seed powder or one or more Mucuna pruriens components, substances, fractions or mixtures or substances obtained therefrom for the preparation of a pharmaceutical composition for preventing, alleviating or treating neurological diseases. Additionally, the invention relates to the use of Mucuna pruriens seeds for the preparation of a pharmaceutical composition for neuroprotection or neurostimulation and to methods of preparing extracts of Mucuna pruriens which can be used for the preparation of a pharmaceutical composition for treating neurological diseases. Finally, the invention relates to the use of Mucuna pruriens seeds for the preparation of a pharmaceutical composition for the treatment of Parkinson's Disease to obtain a broader therapeutic window in L-Dopa therapy, to delay a need for combination therapy, to obtain an earlier onset and longer duration of L-Dopa efficacy, and to prevent or alleviate acute and chronic L-Dopa toxicity.
摘要翻译：本发明提供了包含Mucuna pruriens种子或一种或多种Mucuna pruriens种子组分，从其获得的物质，级分或混合物或物质的药物组合物。此外，本发明涉及用于制备用于预防，减轻或治疗神经疾病的药物组合物的Mucuna pruriens种子粉或一种或多种Mucuna pruriens组分，物质，级分或由其获得的混合物或物质的用途。此外，本发明涉及Mucuna pruriens种子用于制备神经保护或神经刺激的药物组合物的用途，以及可用于制备用于治疗神经疾病的药物组合物的Mucuna pruriens的提取物的方法。最后，本发明涉及Mucuna pruriens种子用于制备用于治疗帕金森病的药物组合物以在L-多巴治疗中获得更广泛的治疗窗口，延迟联合治疗的需要以获得较早发病的用途延长持续时间的L-多巴功效，并预防或缓解急性和慢性左旋多巴的毒性。

7. 发明申请

WO2002087600A1 VERWENDUNG VON PHYLLANTHUSBESTANDTEILEN ZUR BEHANDLUNG ODER PROPHYLAXE VON INFEKTEN DURCH HEPATITIS B-VIREN 审中-公开
标题翻译：叶下珠由病毒治疗或预防乙肝感染中的用途
公开(公告)号：WO2002087600A1
公开(公告)日：2002-11-07
申请号：PCT/EP2002/004641
申请日：2002-04-26
申请人： PHYTRIX AG , OTT, Michael , MANNS, Michael, P.
发明人： OTT, Michael , MANNS, Michael, P.
IPC分类号： A61K35/78
CPC分类号： A61K36/47 , Y02A50/387 , Y10S514/894 , A61K2300/00
摘要： Die Erfindung betrifft die Verwendung von einem oder mehreren Phyllanthusbestandteil(en) oder daraus gewonnenen Stoffen oder Stoffgemischen zur Prävention oder Behandlung von Infektionskrankheiten, die durch ein Hepatitis B Virus, das resistent gegen Nucleosid Analoga ist, hervorgerufen werden oder an deren Entwicklung oder Progression ein Hepatitis B Virus, das resistent gegen Nucleosid Analoga ist, beteiligt ist. Weiterhin betrifft die Erfindung die Verwendung von einem oder mehreren Phyllanthusbestandteil(en) oder daraus gewonnenen Stoffen oder Stoffgemischen zur Herstellung eines Arzneimittels zur Prävention oder Behandlung von Infektionskrankheiten, die durch ein Hepatitis B Virus, das resistent gegen Nucleosid Analoga ist, hervorgerufen werden oder an deren Entwicklung oder Progression ein Hepatitis B Virus, das resistent gegen Nucleosid Analoga ist, beteiligt ist. Des weiteren betrifft die Erfindung die Verwendung von einem oder mehreren Phyllanthusbestandteil(en) oder daraus gewonnenen Stoffen oder Stoffgemischen zur Inhibierung der Vermehrung eines Hepatitis B Virus, das resistent gegen Nucleosid Analoga ist. Weiterhin betrifft die Erfindung Verfahren zur Prävention oder Behandlung von Infektionskrankheiten bei einem Säuger, die durch ein Hepatitis B Virus, das resistent gegen Nucleosid Analoga ist, hervorgerufen werden oder an deren Entwicklung oder Progression ein Hepatitis B Virus, das resistent gegen Nucleosid Analoga ist, beteiligt ist, wobei dem Säuger ein oder mehrere Phyllanthusbestandteil(e) oder daraus gewonnene Stoffe oder Stoffgemische verabreicht wird. Ferner betrifft die Erfindung Verfahren zur Inhibierung der Vermehrung eines Hepatitis B Virus, das resistent gegen Nucleosid Analoga ist, wobei man einen oder mehrere Phyllanthusbestandteil(e) oder daraus gewonnene Stoffe oder Stoffgemische mit den Viren in Kontakt bringt. In einer bevorzugten Ausführungsform der Erfindung sind die Nucleosid Analoga ausgewählt aus der Gruppe bestehend aus Lamivudine und Famciclovir.
摘要翻译：本发明涉及使用一个或多个余甘成分（S）的或衍生的用于预防或治疗感染性疾病，这是由乙型肝炎病毒，其是耐核苷类似物，或它们的发展或进展肝炎引起的物质或组合物乙肝病毒是对核苷类似物耐药，是参与。此外，本发明涉及使用一个或多个余甘成分（S）或者衍生的物质或物质混合物的用于感染性疾病，其由乙型肝炎病毒具有抗性引起核苷类似物，或预防或治疗的药物中的用途及其发展或进展乙型肝炎病毒是耐核苷类似物，它参与。本发明还涉及使用一种或多种余甘成分（S）或者衍生的物质或组合物用于抑制乙型肝炎病毒这是核苷类似物有抗性的增殖。此外，本发明涉及一种用于预防或治疗感染性疾病中引起的乙型肝炎病毒是耐核苷类似物，或它们的发展或进展的B型肝炎病毒，其是核苷类似物有抗性的哺乳动物，所涉及的方法，其中所述哺乳动物的一个或多个叶下珠成分（S）或者其衍生的物质或物质的混合物给药。此外，本发明涉及用于抑制乙型肝炎病毒这是核苷类似物，其中一个或多个叶下珠属成分（S）或其衍生物质或物质混合物与病毒的抵接抗性的增殖的方法。在本发明的一个优选的实施方案中，核苷类似物选自拉米夫定和泛昔洛韦的组中选择。

8. 发明授权

US07470441B2 Method for preparing Mucuna pruriens seed extract 有权
标题翻译： Mucuna pruriens种子提取物的制备方法
公开(公告)号：US07470441B2
公开(公告)日：2008-12-30
申请号：US10533135
申请日：2003-10-02
申请人： Rob Van Der Giessen , C. Warren Olanow , Andrew Lees , Hildebert Wagner
发明人： Rob Van Der Giessen , C. Warren Olanow , Andrew Lees , Hildebert Wagner
IPC分类号： A61K36/48
CPC分类号： A61K36/48
摘要： The present invention provides pharmaceutical compositions comprising Mucuna pruriens seeds or one or more Mucuna pruriens seed components, substances, fractions or mixtures or substances obtained therefrom. Furthermore, the invention relates to the use of Mucuna pruriens seed powder or one or more Mucuna pruriens components, substances, fractions or mixtures or substances obtained therefrom for the preparation of a pharmaceutical composition for preventing, alleviating or treating neurological diseases. Additionally, the invention relates to the use of Mucuna pruriens seeds for the preparation of a pharmaceutical composition for neuroprotection or neurostimulation and to methods of preparing extracts of Mucuna pruriens which can be used for the preparation of a pharmaceutical composition for treating neurological diseases. Finally, the invention relates to the use of Mucuna pruriens seeds for the preparation of a pharmaceutical composition for the treatment of Parkinson's Disease to obtain a broader therapeutic window in L-Dopa therapy, to delay a need for combination therapy, to obtain an earlier onset and longer duration of L-Dopa efficacy, and to prevent or alleviate acute and chronic L-Dopa toxicity.
摘要翻译：本发明提供了包含Mucuna pruriens种子或一种或多种Mucuna pruriens种子组分，从其获得的物质，级分或混合物或物质的药物组合物。此外，本发明涉及用于制备用于预防，减轻或治疗神经疾病的药物组合物的Mucuna pruriens种子粉或一种或多种Mucuna pruriens组分，物质，级分或由其获得的混合物或物质的用途。此外，本发明涉及Mucuna pruriens种子用于制备神经保护或神经刺激的药物组合物的用途，以及可用于制备用于治疗神经疾病的药物组合物的Mucuna pruriens的提取物的方法。最后，本发明涉及Mucuna pruriens种子用于制备用于治疗帕金森病的药物组合物以在L-多巴治疗中获得更广泛的治疗窗口，延迟联合治疗的需要以获得较早发病的用途延长持续时间的L-多巴功效，并预防或缓解急性和慢性左旋多巴的毒性。

9. 发明授权

EP1567177B1 MUCUNA PRURIENS AND EXTRACTS THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISEASES 有权
标题翻译：刺毛黧豆及其提取物用于治疗神经疾病的治疗
公开(公告)号：EP1567177B1
公开(公告)日：2008-04-23
申请号：EP03809721.8
申请日：2003-10-02
申请人： Phytrix AG
发明人： VAN DER GIESSEN, Robert H.M. , OLANOW, Waren, C. , LEES, Andrew , WAGNER, Hildebert
IPC分类号： A61K36/48 , A61P25/16 , A61P25/28
CPC分类号： A61K36/48
摘要： The present invention provides pharmaceutical compositions comprising Mucuna pruriens seeds or one or more Mucuna pruriens seed components, substances, fractions or mixtures or substances obtained therefrom. Furthermore, the invention relates to the use of Mucuna pruriens seed powder or one or more Mucuna pruriens components, substances, fractions or mixtures or substances obtained therefrom for the preparation of a pharmaceutical composition for preventing, alleviating or treating neurological diseases. Additionally, the invention relates to the use of Mucuna pruriens seeds for the preparation of a pharmaceutical composition for neuroprotection or neurostimulation and to methods of preparing extracts of Mucuna pruriens which can be used for the preparation of a pharmaceutical composition for treating neurological diseases. Finally, the invention relates to the use of Mucuna pruriens seeds for the preparation of a pharmaceutical composition for the treatment of Parkinson's Disease to obtain a broader therapeutic window in L-Dopa therapy, to delay a need for combination therapy, to obtain an earlier onset and longer duration of L-Dopa efficacy, and to prevent or alleviate acute and chronic L-Dopa toxicity.

10. 发明专利

PT1333848E COMPOSTOS DERIVADOS DE PHYLLANTUS PARA A PREVENCAO E/OU O TRATAMENTO DE DOENCAS ASSOCIADAS COM UM RETROVIRUS 未知
公开(公告)号：PT1333848E
公开(公告)日：2006-08-31
申请号：PT01986262
申请日：2001-10-05
申请人： PHYTRIX AG
发明人： RALF WAGNER , FRANK NOTKA
IPC分类号： A61K31/366 , A61K31/7024 , A61K36/47 , A61P31/14 , A61P31/18 , A61P31/00

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式